EXTEND: NOVEL OXYGEN THERAPEUTIC NANO2 FOR MILD RESPIRATORY DISTRESS IN PHASE IB AND ARDS IN PHASE II TRIALS

Registry ID

EXTEND-P2

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

NUVOX PHARMA LLC

Start date

2025-01-30

Last update

2021-05-17

Conditions

• CORONAVIRUS DISEASE (COVID-19)
• ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Related clinical trials

• ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR RESPIRATORY INFECTIONS IN COMMUNITY SETTINGS (TREATRESP)
• AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS
• A RANDOMIZED, CONTROLLED, BLINDED, PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF AEROFACT¿ (SF-RI 1 SURFACTANT FOR INHALATION COMBINED WITH A DEDICATED DELIVERY SYSTEM) IN PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROME
• SURFACTANT ADMINISTRATION BY SUPRAGLOTTIC AIRWAY (THE SURFSUP TRIAL)
• PHASE 1/2 STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A PROPHYLACTIC PLASMID DNA BOOSTER VACCINE AGAINST SARS-COV- -002] IN GENERALLY HEALTHY ADULTS 18 YEARS AND OLDER
• A PHASE 2 TRIAL TO EVALUATE SAFETY AND IMMUNOGENICITY OF A NEXT-GENERATION COVID-19 VACCINE DELIVERED BY INHALED AEROSOL TO HUMANS

View on source registry